← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2011Last known activity
Jul 11, 2024
Timeline
1990s
- Jan 1, 1998
Intrexon— Founded
2010s
- Feb 2, 2011
Agarigen— Acquired
- Oct 24, 2011
Immunologix— Acquired
- Dec 20, 2013
Medistem— Acquired
- Feb 13, 2015
ActoGeniX— Acquired
- Aug 10, 2015
Oxitec— Acquired
- Feb 25, 2016
EnviroFlight— Acquired
- Jan 24, 2017
GenVec— Acquired
Drugs by trial phase (30 distinct, 27 trials)
Phase 3 (1 own, 1 via acquisition)
Phase 2 (5 own, 3 via acquisition)
Indications
Studied for
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Cardiovascular Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Epidermolysis Bullosa
- Epidermolysis Bullosa Dystrophica
- Fallopian Tube Neoplasms
- Heart Failure
- Leukemia
- Leukemia, Biphenotypic, Acute
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Myelodysplastic Syndromes
- Neoplasm, Residual
- Neoplasms
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
Subsidiaries (7 direct, 7 total across the full acquisition tree)
Recent trials (18)
- NCT06538480OfficialPhase 3Jul 11, 2024
- NCT06538480Lead sponsorPhase 3Jul 11, 2024
- NCT06157151Lead sponsorPhase 2Dec 3, 2023
- NCT05694364CollaboratorPhase 1Jan 25, 2023
- NCT04724980Lead sponsorPhase 1Mar 16, 2021
- NCT04724980Study directorPhase 1Mar 16, 2021
- NCT03927261CollaboratorPhase 1May 17, 2019
- NCT03907527Study directorPhase 1Apr 30, 2019
- NCT03907527Lead sponsorPhase 1Apr 30, 2019
- NCT03579888CollaboratorPhase 1Jan 31, 2019
- NCT03751007Lead sponsorPhase 1/Phase 2Oct 27, 2018
- NCT03409627CollaboratorPhase 1Apr 9, 2018
- NCT03409627Lead sponsorPhase 1Apr 9, 2018
- NCT03126864CollaboratorPhase 1Jun 1, 2017
- NCT02810951CollaboratorPhase 1/Phase 2Jul 1, 2016
Details
- Founded
- Blacksburg, VA, US Jan 1, 1998
- Last known activity
- Jul 11, 2024